← Leaderboards
Andras Gruber
Oregon Health And Science University
$4,797,747
Attributed
$8,935,764
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–17$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$8,935,764 · 16
By mechanism
R44$7,978,549 · 3
P51$659,729 · 12
R43$297,486 · 1
Top collaborators
- Erik Ian Tucker10 shared
Others in their field
Top investigators on “Grant”
- David R. Weir · University Of Michigan At Ann Arbor$373,949,788
- David Heimbrook · Leidos Biomedical Research, Inc.$341,196,902
- Eric S Lander · Whitehead Institute For Biomedical Res$323,181,457
- Jeffrey P Krischer · University Of South Florida$258,583,867
- Lawrence Corey · Fred Hutchinson Cancer Center$253,286,867
- Barton F Haynes · Duke University$243,251,908
Research focus
GrantHemostatic FunctionPrimatesFundingAnticoagulantsThrombosisResearch PersonnelAdverse EffectsHemorrhagePharmaceutical PreparationsProtein CMedicalAnticoagulationImpairmentBlood CoagulationDoseThrombusEnzymesResourcesCoagulation ProcessInvestigational DrugsSafetyLeadIschemic Stroke
Grant awards (22)
Therapeutic factor XI blockade for sepsis$359,659
R44 · FY2017 · HL
Therapeutic factor XI blockade for sepsis$997,083
R44 · FY2016 · HL
Therapeutic Thrombin Analogs$872,549
R44 · FY2016 · HL
Therapeutic factor XI blockade for sepsis$999,329
R44 · FY2015 · HL
Therapeutic Thrombin Analogs$957,597
R44 · FY2015 · HL
Therapeutic factor XI blockade for sepsis$983,121
R44 · FY2014 · AI
Therapeutic Thrombin Analogs$834,603
R44 · FY2014 · HL
Therapeutic factor XI blockade for sepsis$974,608
R44 · FY2013 · AI
Therapeutic factor XI blockade for sepsis$1,000,000
R44 · FY2012 · AI
EVALUATION OF PROTEASE ACTIVATED RECEPTOR (PAR) ANTAGONISTS$36,286
P51 · FY2011 · RR · contact PI
Therapeutic factor XI blockade for sepsis$297,486
R43 · FY2010 · AI
EVALUATION OF PROTEASE ACTIVATED RECEPTOR (PAR) ANTAGONISTS$47,603
P51 · FY2010 · RR · contact PI
EVALUATION OF PROTEASE ACTIVATED RECEPTOR (PAR) ANTAGONISTS$80,343
P51 · FY2009 · RR · contact PI
ANTICOAGULANT THROMBINS IN VITRO AND IN VIVO$55,512
P51 · FY2008 · RR · contact PI
REVERSAL OF ANTICOAGULANTS IN VIVO$55,512
P51 · FY2008 · RR · contact PI
THROMBOSIS-SPECIFIC ANTICOAGULATION$27,704
P51 · FY2008 · RR · contact PI
ANTICOAGULANT THROMBINS IN VITRO AND IN VIVO$75,850
P51 · FY2007 · RR · contact PI
THROMBOSIS-SPECIFIC ANTICOAGULATION$37,926
P51 · FY2007 · RR · contact PI
REVERSAL OF ANTICOAGULANTS IN VIVO$14,673
P51 · FY2007 · RR · contact PI
ANTICOAGULANT THROMBINS IN VITRO AND IN VIVO$76,828
P51 · FY2006 · RR · contact PI
THROMBOSIS-SPECIFIC ANTICOAGULATION$76,828
P51 · FY2006 · RR · contact PI
ANTICOAGULANT THROMBINS IN VITRO AND IN VIVO$74,664
P51 · FY2005 · RR